# CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

> **NCT03998163** · PHASE3 · COMPLETED · sponsor: **Cara Therapeutics, Inc.** · enrollment: 222 (actual)

## Conditions studied

- Uremic Pruritus

## Interventions

- **DRUG:** CR845 0.5 mcg/kg

## Key facts

- **NCT ID:** NCT03998163
- **Lead sponsor:** Cara Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-06
- **Primary completion:** 2020-02-26
- **Final completion:** 2020-03-06
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2021-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03998163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03998163, "CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03998163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*